Jennifer Smith is the editor of Oncology Practice, part of MDedge Hematology/Oncology. She was previously the editor of Hematology Times, an editor at Principal Investigators Association, and a reporter at The Oneida Daily Dispatch. She has a BS in journalism.
News

Umbralisib gains FDA breakthrough designation for MZL
- Author:
- Jennifer Smith
Umbralisib is a PI3K-delta inhibitor being developed for the treatment of adults with marginal zone lymphoma.
News

Combo treatment may improve quality of life in CTCL
- Author:
- Jennifer Smith
LA JOLLA, CALIF. – In a small study, patients experienced relief from pruritus after just one cycle of treatment with brentuximab vedotin plus...
News

Are single agents better than chemo for relapsed/refractory PTCL?
- Author:
- Jennifer Smith
LA JOLLA, CALIF. – Complete response rates and survival times were better among patients who received single-agent therapy.
Video

Four-drug combo shows durable responses in relapsed/refractory lymphomas
- Author:
- Jennifer Smith
LA JOLLA, CALIF. – The phase 1 study tested the addition of a histone deacetylase inhibitor to platinum-based chemotherapy.
News

FDA approves third trastuzumab biosimilar
- Author:
- Jennifer Smith
The drug is approved for treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction...
News

Long-term mogamulizumab appears safe, effective in CTCL
- Author:
- Jennifer Smith
LA JOLLA, CALIF. – Investigators said that prolonged treatment with the drug does not appear to pose an increased safety risk.
News

Zanubrutinib receives breakthrough designation for MCL
- Author:
- Jennifer Smith
The Bruton’s tyrosine kinase inhibitor was evaluated in a phase 2 trial.
News

Chidamide may be more effective in PTCL than previously thought
- Author:
- Jennifer Smith
LA JOLLA, CALIF. – Chidamide produced a higher response rate in relapsed/refractory PTCL patients than what was observed in a prior phase 2 trial...
Video

Epigenetics is a hot topic at TCLF 2019
- Author:
- Jennifer Smith
LA JOLLA, CALIF. – New developments include using epigenetic therapy to enhance immune checkpoint therapy and using epigenetic-based combination...
News

Registry data favor CHOEP regimen for PTCL
- Author:
- Jennifer Smith
LA JOLLA, CALIF. – Registry data have influenced the treatment of patients with PTCL in the Czech Republic.
News

FDA approves new ALL treatment for children, young adults
- Author:
- Jennifer Smith
The asparagine-specific enzyme is approved as part of a multiagent chemotherapy regimen.
News

FDA expands dasatinib indication to children with Ph+ ALL
- Author:
- Jennifer Smith
The FDA approved dasatinib in combination with chemotherapy for children with newly diagnosed disease.
News
Checkmate 436: Two-drug combo is ‘promising’ for PMBCL
- Author:
- Jennifer Smith
SAN DIEGO – The early results suggest a high overall response to the drug combination.
News

ECHELON-2: BV-CHP boosts survival in PTCL
- Author:
- Jennifer Smith
SAN DIEGO – The newly approved regimen outperformed the standard CHOP regimen in this rare cancer.
News
Phase 3 data support apixaban for cancer-associated VTE
- Author:
- Jennifer Smith
The rate of major bleeding was similar with apixaban and dalteparin.